Clinical Trials · NCT05162183
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 3,474
- Start date
- Sep 2019
- Locations
- 1 site, United States
- Primary endpoint
- Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up)